指南与共识系统性红斑狼疮

欧洲儿童起病狼疮性肾炎诊断与治疗循证推荐:SHARE 倡议

European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative.
指南 / 共识 · Ann Rheum Dis · 2017-09-06

SHARE 倡议依据 EULAR 标准操作流程制定儿童起病狼疮性肾炎诊断与治疗推荐,由含儿童肾脏科代表的欧洲专家委员会以名义群体技术形成共识,共接受 6 条诊断推荐和 20 条治疗推荐,覆盖 ISN/RPS 2003 分类各型狼疮性肾炎。

要点

  • 治疗目标应为完全肾脏缓解
  • III/IV 型诱导用 MMF 或静脉环磷酰胺联合糖皮质激素,维持用 MMF 或硫唑嘌呤至少 3 年
  • 单纯 V 型可用 MMF 联合低剂量泼尼松诱导、MMF 维持

核心结论

  • SHARE 推荐用于支持所有儿童系统性红斑狼疮患者获得统一且高质量的诊疗。

研究设计与样本

  • 采用欧洲抗风湿病联盟(EULAR)标准操作流程制定推荐。
  • 由含儿童肾脏科代表的欧洲专家委员会以名义群体技术形成推荐。

主要发现

  • 共接受 6 条诊断推荐和 20 条覆盖治疗选择与目标的推荐,含 ISN/RPS 2003 分类各型狼疮性肾炎。
  • 狼疮性肾炎发生于 50%–60% 的儿童起病系统性红斑狼疮患者,导致显著疾病负担。

关键数值与推荐

  • 治疗目标应为完全肾脏缓解。
  • I 型狼疮性肾炎治疗主要依据其他症状指导。
  • II 型狼疮性肾炎初始用低剂量泼尼松,仅在持续蛋白尿 3 个月或泼尼松依赖后加用改善病情抗风湿药。
  • III/IV 型诱导用吗替麦考酚酯(MMF)或静脉环磷酰胺联合糖皮质激素,维持用 MMF 或硫唑嘌呤至少 3 年。
  • 单纯 V 型狼疮性肾炎可用 MMF 联合低剂量泼尼松诱导、MMF 维持。

临床怎么用

  • 及时识别肾脏受累并给予适当治疗对预防肾脏损害至关重要。
  • 按 ISN/RPS 2003 分类分型选择诱导与维持方案,并以完全肾脏缓解为治疗目标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lupus nephritis (LN) occurs in 50%-60% of patients with childhood-onset systemic lupus erythematosus (cSLE), leading to significant morbidity. Timely recognition of renal involvement and appropriate treatment are essential to prevent renal damage. The Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative aimed to generate diagnostic and management regimens for children and adolescents with rheumatic diseases including cSLE. Here, we provide evidence-based recommendations for diagnosis and treatment of childhood LN. Recommendations were developed using the European League Against Rheumatism standard operating procedures. A European-wide expert committee including paediatric nephrology representation formulated recommendations using a nominal group technique. Six recommendations regarding diagnosis and 20 recommendations covering treatment choices and goals were accepted, including each class of LN, described in the International Society of Nephrology/Renal Pathology Society 2003 classification system. Treatment goal should be complete renal response. Treatment of class I LN should mainly be guided by other symptoms. Class II LN should be treated initially with low-dose prednisone, only adding a disease-modifying antirheumatic drug after 3 months of persistent proteinuria or prednisone dependency. Induction treatment of class III/IV LN should be mycophenolate mofetil (MMF) or intravenous cyclophosphamide combined with corticosteroids; maintenance treatment should be MMF or azathioprine for at least 3 years. In pure class V LN, MMF with low-dose prednisone can be used as induction and MMF as maintenance treatment. The SHARE recommendations for diagnosis and treatment of LN have been generated to support uniform and high-quality care for all children with SLE.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Groot N, de Graeff N, Marks SD, et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis. 2017. PMID: 28877866. doi:10.1136/annrheumdis-2017-211898

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。